Beraprost
CAS: 88430-50-6
Ref. 3D-FB167395
1mg | A consultar | ||
2mg | A consultar | ||
5mg | A consultar | ||
10mg | A consultar | ||
25mg | A consultar |
Información del producto
- 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-
- 1H-Cyclopenta[b]benzofuran-5-butanoic acid, 2,3,3a,8b-tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-ynyl)-
- 2,3,3a,8b-Tetrahydro-2-hydroxy-1-(3-hydroxy-4-methyl-1-octen-6-yn-1-yl)-1H-cyclopenta[b]benzofuran-5-butanoic acid
- 4-{(1R,2R,3aS,8bS)-2-hydroxy-1-[(1E,3S)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid
- 4-{2-hydroxy-1-[(1E)-3-hydroxy-4-methyloct-1-en-6-yn-1-yl]-2,3,3a,8b-tetrahydro-1H-benzo[b]cyclopenta[d]furan-5-yl}butanoic acid
- Mdl 201229
- Ml 1229
Beraprost is a prostacyclin analogue that is used in the treatment of primary pulmonary hypertension. It has been shown to be effective in the treatment of chronic bowel disease and low-dose group. Beraprost sodium binds to the response element, preventing the binding of transcription factors and inhibiting gene expression. The pyrazole ring is an analogue of prostacyclin that has been shown to inhibit blood clotting as well as brain functions. Beraprost also inhibits platelet aggregation and leukocyte adhesion, thereby reducing inflammation and vascular permeability. Beraprost can be taken orally or by injection.
Propiedades químicas
Consulta técnica sobre: 3D-FB167395 Beraprost
Si desea solicitar un presupuesto o realizar un pedido, por favor añada los productos deseados a su carrito y solicite un presupuesto o pedido desde el carrito. Es más rápido, más barato, y podrá beneficiarse de los descuentos y las ventajas disponibles.